|Bid||0.00 x 21500|
|Ask||36.77 x 4000|
|Day's Range||36.44 - 37.01|
|52 Week Range||30.20 - 37.61|
|PE Ratio (TTM)||160.48|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Qiagen, a German diagnostics company, has confirmed it is expanding its research and development activities in the UK, creating or supporting up to 1,500 jobs, in a move it hailed as a post-Brexit vote of confidence in the country’s science base. by the company, along with another from MSD, known as Merck in North America, last year, as they unveiled an industrial strategy designed to ensure the UK remains an attractive destination for investment post-Brexit. On Wednesday, Health Innovation Manchester, a collaboration involving academics, industry and the NHS, said the joint project would add almost £150m to Manchester’s economy over a decade, directly creating about 250 jobs, safeguarding an extra 215 and supporting more than 1,000 more indirectly.
This article is intended for those of you who are at the beginning of your investing journey and want to better understand how you can grow your money by investingRead More...
QIAGEN's (QGEN) progress with the test menu expansion is impressive. Earlier in Q1, the company also secures the Japanese approval for QuantiFERON-TB Gold Plus as an in vitro diagnostic to detect TB.
QIAGEN (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
A Relative Strength Rating upgrade for Qiagen shows improving technical performance. Will it continue?
The Venlo, Netherlands-based company said it had net income of 14 cents per share. Earnings, adjusted for non-recurring costs, came to 26 cents per share. The results beat Wall Street expectations. The ...
QIAGEN N.V. (QGEN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.
QIAGEN's (QGEN) QuantiFERON-TB diagnostic test kit falls under QIAGEN's Molecular Diagnostics segment, which was the highest revenue grosser in the last reported quarter.
Becton, Dickinson's (BDX) strategic acquisition of C.R. Bard provides it a strong foothold and exposure in MedTech. Here we take a look at five other factors that are likely to boost the stock.
Becton, Dickinson and Company's (BDX) PAXgene ccfDNA gets a commercial launch in Europe and enables improved DNA testing in comparison to standard EDTA tubes.
QIAGEN (QGEN) continues to strengthen Molecular Diagnostics business with focus on expanding QuantiFERON-TB Gold Plus customer base.
QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and declining HPV sales.